Boxer Capital TNGX Position
Exited14-Fund ConvergenceBoxer Capital exited their position in Tango Therapeutics Inc. (TNGX) in Q4 2024, after holding the stock for 12 quarters.
The position was first reported in Q1 2022 and has been tracked across 12 quarterly 13F filings.
TNGX is a convergence signal: 14 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for TNG462 in 47 days (May 31, 2026), making the timing of Boxer's position particularly relevant.
Short interest stands at 38.0% of float with 12.2 days to cover, indicating significant bearish positioning against the stock.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Full company profile →Short Interest
38.0%
12.2 days to cover
Boxer Capital TNGX Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2024 | Exited | 0 | -8,198,642 | $0 |
| Q3 2024 | Held | 8,198,642 | — | $63.1M |
| Q2 2024 | Held | 8,198,642 | — | $70.3M |
| Q1 2024 | Held | 8,198,642 | — | $65.1M |
| Q4 2023 | Increased | 8,198,642 | +1,075,000 | $81.2M |
| Q3 2023 | Held | 7,123,642 | — | $80.2M |
| Q2 2023 | Held | 7,123,642 | — | $23.6M |
| Q1 2023 | Held | 7,123,642 | — | $28.1M |
| Q4 2022 | Increased | 7,123,642 | +252,000 | $51.6M |
| Q3 2022 | Held | 6,871,642 | — | $24.9M |
| Q2 2022 | Held | 6,871,642 | — | $31.1M |
| Q1 2022 | New | 6,871,642 | +6,871,642 | $52.1M |
Frequently Asked Questions
Does Boxer Capital own TNGX?
No. Boxer Capital exited their position in Tango Therapeutics Inc. (TNGX) in Q4 2024. They previously held the stock for 12 quarters.
How many hedge funds own TNGX?
14 specialist biotech hedge funds currently hold TNGX, including EcoR1 Capital, Perceptive Advisors, Deerfield Management and 11 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Boxer Capital first buy TNGX?
Boxer Capital's position in TNGX was first reported in Q1 2022. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Boxer Capital's TNGX position increasing or decreasing?
Boxer Capital completely exited their TNGX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
TNGXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Boxer CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →